95 related articles for article (PubMed ID: 27841152)
1. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
[TBL] [Abstract][Full Text] [Related]
2. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
[TBL] [Abstract][Full Text] [Related]
5. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
[TBL] [Abstract][Full Text] [Related]
6. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
Kardos P; Hagedorn-Peinz I
Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.
Lehmann S; Ringbæk T; Løkke A; Grote L; Hedner J; Lindberg E
Int J Chron Obstruct Pulmon Dis; 2019; 14():199-210. PubMed ID: 30666100
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
[TBL] [Abstract][Full Text] [Related]
11. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
[TBL] [Abstract][Full Text] [Related]
12. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
[TBL] [Abstract][Full Text] [Related]
13. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
[TBL] [Abstract][Full Text] [Related]
16. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R; Banerji D
Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
[TBL] [Abstract][Full Text] [Related]
17. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
Pelaia C; Crimi C; Crimi N; Ricciardi L; Scichilone N; Valenti G; Bonavita O; Andaloro S; Morini P; Rizzi A; Pelaia G
Expert Rev Respir Med; 2022 Feb; 16(2):183-195. PubMed ID: 34845963
[TBL] [Abstract][Full Text] [Related]
18. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D; Wild JM; Saralaya D; Lawson R; Marshall H; Goldin J; Brown MS; Kostikas K; Belmore K; Fogel R; Patalano F; Drollmann A; Machineni S; Jones I; Yates D; Tillmann HC
Respir Res; 2022 Feb; 23(1):26. PubMed ID: 35144620
[TBL] [Abstract][Full Text] [Related]
19. Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance.
Kato C; Yoshisue H; Nakamura N; Sasajima T
Intern Med; 2022 Mar; 61(6):789-800. PubMed ID: 34483208
[TBL] [Abstract][Full Text] [Related]
20. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
de Llano LP; Naval E; Mejía N; Domínguez-Ortega J
Expert Rev Respir Med; 2022 Jan; 16(1):1-15. PubMed ID: 34783265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
